CD274 and small cell lung carcinoma: A recent study showed that the addition of anti-VEGF therapy to an anti-PD-L1 regimen could synergistically improve the outcome of the anti-PD-L1 treatment by using an autochthonous mouse model of SCLC, a model that is less sensitive to anti-PD-L1 treatment [28].